Novel Flu Vaccines Lots of choices
|
|
- Katherine Mercy Randall
- 5 years ago
- Views:
Transcription
1 Novel Flu Vaccines Lots of choices Universal M2 ectodomain (A types, only) Universal HA cleavage site (A and B types) HA made by rdna methods (not eggs or mammalian cells) Vectored delivery of HA genes T cell vaccines to conserved internal proteins Engineered influenza viruses (NS1)
2 HA Based Vaccines Protein Sciences: HA in insect cells (baculo) Novavax: HA NA M1 VLPs in insect cells VaxInnate: HA globular head fused to flagellin Vical: Formulated plasmid DNA AlphaVax: HA expressed in alphavirus vector Hawaii Biotech: insect cell VLPs Frauenhofer & Medicago: VLPs in tobacco leaves Monoclonal antibody based vaccines
3 Live virus approaches Green Hills: Live attenuated NS1 mods Vivaldi: Live attenuated NS1 mutants BioDiem: Leningrad 57 Live attenuated Medimmune AZ: Flumist (NIAID) Vaxin: Adenovirus vector, nasal delivery Vaxart: Adenovirus vector capsule delivery of antigen and TLR3 dsrna
4 M2e Vaccines Merck (M2e plus cleavage site) OMPC, alum, Iscomatrix (QS21) Acambis (M2e x3 on HBcAg, alum, QS21) Dynavax (M2e x8 fused to NSP+CpG) VaxInnate (M2e x4 fused to flagellin)
5 M2e The ectodomain of M2 presented as a homotetramer ion channel. Note that no true 3D structure has been determined for M2e
6 Spectrum of M2e Sequences 3 of the recent HIN1 isolates: TEVETPTRSEWECRCSDSSDP TEVETPTRSEWECRCSDSSDP TEVETPTRSEWECRCSDSSDP H1/H2/H3 consensus SLLTEVETPIRNEWGSRSNDSSDP A/New Caledonia/20/99 H1N1 human SLLTEVETPIRNEWGCRCNDSSDP A/Aichi/470/68 H3N1 human SLLTEVETPIRNEWGCRCNDSSDP A/Ann Arbor/6/60 H2N2 human SLLTEVETPIRNEWGCRCNDSSDP A/Berkeley/1/68 H2N2 human SLLTEVETPIRNEWGCRCNDSSDP A/Puerto Rico/8/34 H1N1 human SLLTEVETPIRNEWGCRCNGSSDP A/Wisconsin/3523/88 H1N1 human SLLTEVETPIRNEWGCKCNDSSDP A/Hebei/19/95 H3N2 human SLLTEVETPIRNEWECRCNGSSDP A/Swine/2009 H1N1 human SLLTEVETPTRSEWECRCSDSSDP H5 consensus SLLTEVETPTRNEWESRSSDSSDP A/Viet Nam/1203/2004 H5N1 human SLLTEVETPTRNEWECRCSDSSDP A/Chicken/Nakorn- Patom/Thailand H5N1 avian SLLTEVETPTRNEWECRCSDSSDP A/Thailand/1(KAN-1)/04 H5N1 avian SLLTEVETPTRNEWECRCSDSSDP A/Duck/1525/81 H5N1 avian SLLTEVETPTRNGWECKCSDSSDP A/Hong Kong/156/97 H5N1 human SLLTEVETLTRNGWGCRCSDSSDP A/Chicken/New York/95 H7N2 avian SLLTEVETPTRNGWECKCSDSSDP A/Chicken/Hong Kong/G9/97 H9N2 avian SLLTEVETPTRNGWGCRCSGSSDP A/Hong Kong/1073/99 H9N2 human SLLTEVETLTRNGWECKCRDSSDP
7 Acambis HBcAg Three copies in tandem presented on HepB core antigen
8 TLR2, OMPC, Merck M2e peptides chemically conjugated to outer membrane complex from N. meningitidis
9 TLR5, flagellin, VaxInnate Four copies of the M2e sequence fused to the sequence of flagellin
10 TLR9, CpG Eight copies of the M2e sequence fused to the NP protein and conjugated to CpG containing oligonucleotide
11 Bacteriophage Q, Cytos M2e sequence displayed on the phage Qβ
12 Innate Immune Responses are Mediated by Toll like Receptors Expressed on the Surface of Immune Cells Toll Like Receptors Recognize Pathogen Associated Patterns (PAMPs) 12 VaxInnate s current influenza vaccines incorporate flagellin, a TLR5 ligand, and only well studied protein agonist
13 PAMP TLR Endoplasmic Reticulum IL 12 T H 1 Endocytic PRR CD80/86 CD28 Pathogen Phagosome MHC I or II TCR T Cell Dendritic Cell Nucleus T H 2
14 Influenza Vaccines Importance of Fusion to Flagellin Conventional Adjuvants Ag specific immune response Excessive inflammatory response Non specific immune response Autoimmune response Ag specific immune response Minimal inflammatory response VaxInnate s vaccines = antigen 14 Genetic Fusions of the Vaccine Antigen and TLR Ligand Efficiently Stimulate both the Innate and Adaptive Immune Systems and Mimic Natural Infection.
15 VAX102: Low Dose & Alternative Routes Longitudinal anti M2e Responses for Doses Spanning 0.03 to 10 mg ug 0.3 ug Anti-M2e Geometric Mean Titers ug/ml anti-m2e IgG ug 1ug 0.1 ug (IM) 0.1 ug (ID) 0.03 ug (IM) 0.03 ug (ID) 0.50 cutoff 0.00 Dy 0 Dy 7 Dy 14 Dy 28 Dy 35 Dy 42 Dy 60 Dy 120 Dy 180 Low doses of VAX102 delivered on days 0 and 28 elicit robust anti M2e titers that remain above the positive cutoff for 6 months 15 Note good prime and especially the boost after the day 28 dose. Boost is not affected by flagellin antibody raised by the prime
16 Other Conserved Antigens Stalk cleavage site Stalk straight alpha helix Headless stalk Matrix, NP as T cell targets
17 Influenza Vaccine HA Subunit Vaccine Design HA Globular Head Flagellin HA Trimer HA Monomer Fusion of HA globular head (HA1 2) and S. typhimurium flagellin type 2 (STF2) [a TLR5 ligand] to form STF2.HA1 2 VaxInnate's HA subunit vaccines can be produced in E.coli 17
18 HA Cleavage Site, Merck Re drawn from Bianchi, et al., ref 26
19 Peter Palese, Adolfo Garcia Sastre, Mount Sinai
20 Broadly Neutralizing Monoclonals , Crucell and NIH broadly neutralizing antibodies (both the same germline sequence) binding to stalk (fusion intermediate) Bommakanti, et al (Nehru Crucell Merck) antigen designed from MAb binding site 2011, Corti et al., stalk binding monoclonal FI6 Eikert, et al, Group 2 stalk binding monoclonal
21 Corti, et al, Science, 2011
22 How do you turn a MAb into a vaccine? Passive protection, 4 10 mgs/kg reported At catalog price for Synagis (RSV antibody, premature infants) one dose for a 100 kg vaccine developer is $20,000 Use MAb binding site as target antigen Will require full clinical development program since no correlate of protection exists for the target (such as HAI)
23 Bommakanti et al
24 What Matters in a Pandemic? TIME! Time to make seed stock Time to build biomass Time to produce antigen Time to harvest purify (doses per unit time) Time to test for release of bulk Time to package and release Time to ship
25 What Matters? Time to last dose to cover intended population Time to first dose is false comfort Swimming pool analogy (how long to fill?) Garden hose Fire hose It s all about throughput and getting out of eggs, the biological bottleneck!
26
27 Virus Like Particles, Tobacco Landry et al. Medicago
28
29 Virus Like Particles made in insect cells
30
31 Vectored Gene Delivery Vaxin, replication deficient adenovirus vectors expressing HA, delivered intranasally Vaxart, replication deficient adenovirus vectors expressing HA plus dsrna (TLR3), delivered via oral capsule MVA expressing conserved conserved antigens Inovio, electroporation of plasmid DNA Vical, injection of formulated DNA
32 Engineered Influenza Viruses (Palese Lab, Mt Sinai) Nine segment virus (two different HA genes) Reassortment incompetent viruses NS1 modifications (Palese, AVIR Green Hills) NS1 encodes an inhibitor of poly adenylated RNA Also encodes a viral rnp export protein Interferes with interferon response of infected cell
33 Influenza Vaccine HA Subunit Vaccine Design HA Globular Head Flagellin HA Trimer HA Monomer Fusion of HA globular head (HA1 2) and S. typhimurium flagellin type 2 (STF2) [a TLR5 ligand] to form STF2.HA1 2 VaxInnate's HA subunit vaccines can be produced in E.coli 33
34 Seasonal Vaccines VAX125 Immunogenicity in Man Phase I Clinical Evaluation Prototype (one component) seasonal influenza vaccine, VAX125: Dose response of antibody formulation in adults years of age Antibody Titer Day Placebo Dose (ug) 34 Immunogenicity for doses of 1 µg or above is excellent in healthy adults (18 45 years old)
35 Whole Virion and Adjuvanted Split Virus Immune Response Immune response to single dose whole virion (WV, Baxter, 7.5 ug) and ASO3 adjuvanted split virus (ASO3, GSK, 3.75 ug) H1N1 CA7/2009 vaccine in different age groups Whole virion ASO3 adjuvanted n=70 n=68 n=34 n=70 n=68 n=37 GMT day GMT day MFR SP % SC % from Nicholson et al. Lancet Infectious Diseases 2010 Adjuvanted vaccine is more immunogenic, but performance in the elderly is modest 35
36 VAX 125 HAI Response in the Elderly Peak GM HAI response 14 days after VAX125 among subjects 65 years old (left panel). GM HAI titers measured from day 0 to 28 after a single dose of VAX125 ranging from 0.5 to 8 µg among subjects 65 years old (right panel) HAI Titers (GMT+95%CI) Dose (ug) HAI titer (SI) Day Elderly adults respond to higher vaccine doses 36
37 HA Subunit Vaccines Development of Alternative Vaccine Formats D0 D0 D0 D1 D3 D2 D1 D2 D2 D1 C Term = A (Antigen Attached to C terminus) R3 = B (Antigen Replaces D3 Domain) R3.2x = C (2 Antigens Fused to Flagellin) Alternative vaccine formats, which differ in the point of antigen attachment to flagellin were developed, initially, to improve the potency of poorly immunogenic H5 HA vaccines 37
38 VAX HAI Response Serum HAI response for VAX128C in VAX VAX128C dose (µg) 1.25 (n=47) 2.5 (n=50) Total (n=97) GMT 95% C.I. GMT 95% C.I. GMT 95% C.I. GMT Day GMT Day Mean fold resp % % % Seroconversion Seroprotection
39 VAX 128C GMT HAI, SC & SP HAI titers, Seroconversion (SC) and Seroprotection (SP) rates after a single IM dose of VAX128C (CA07) Age group Total Dose (µg) n= GMT HAI day GMT HAI day Mean fold response Seroconversion % Seroprotection %
40 VaxInnate s E. Coli Based Manufacturing High Efficiency & Large Capacity Manufacturing Influenza Vaccine for the US Substrate Cost of Recently Built Facilities (without validation) Time to build and Validate New Facility Annual Capacity (TIV) Eggs $150 million > 3 years 100 million Cell Culture $680 million > 3 years 50 Million Baculovirus $40 million > 2 years 100 Million E. coli/vaxinnate $0 (CMO) 0 years million* *VaxInnate's capacity is based on performing a single 1,000 liter run for each antigen included in the vaccine. Yields differ by antigen and construct. 40
41 What s Next? New vaccines will face long and expensive development programs (efficacy based) HA based vaccines have advantage of correlate of protection (HAI) Current low incidence of flu (infant vax?) makes trial size much larger US universal recommendation makes placebo trial impossible, go somewhere else? Major focus on better vaccine for elderly
Clinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationLive Attenuated Influenza Vaccine. I. Background and Seasonal Vaccine
Live Attenuated Influenza Vaccine I. Background and Seasonal Vaccine Influenza infection stimulates multiple arms of the immune system Systemic antibody to HA and NA, and multiple internal proteins Mucosal
More informationBiotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Biotechnology-Based Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1.
More informationPATH Influenza Vaccine Projects
PATH Influenza Vaccine Projects Overview John W. Boslego, MD John Boslego Director, Vaccine Development Global Program March 25 th, 2014 Influenza Vaccine Project (IVP) at PATH IVP Goal: Advance the development
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationAvian influenza and pandemic threats
Avian influenza and pandemic threats Philippe BUCHY MD, PhD Head of Virology Unit Director NIC Cambodia Vaccinology 2013 Bangkok, 11-13 November 2013 Influenza viruses Influenza viruses (Orthomyxoviridae)
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationHemagglutinin-stalk specific antibodies: How to induce them and how to measure them
Immunodominant head domain Stalk domain Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them Florian Krammer Icahn School of Medicine at Mount Sinai May 5 th 2014 2 nd WHO
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationRe-engineering HA as a strategy to develop universal influenza vaccines
WHO Integrated Meeting on Development & Clinical Trials of Influenza Vaccines Re-engineering HA as a strategy to develop universal influenza vaccines Harry Kleanthous, Ph.D. Discovery Research January
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationCanadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationTOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor
More informationDevelopment of influenza vaccine production by means of chromatographic methods
Development of influenza vaccine production by means of chromatographic methods WHO meeting on prospects for influenza vaccine technology transfer to vaccine manufacturers of developing countries. 27-28
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationAn Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes. Nick Poulton June September 2012
An Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes Nick Poulton June 2012- September 2012 Epidemiology of Influenza Infection Causes between 250,000
More informationVaccine Update March 28, 2018
Vaccine Update March 28, 2018 Paul A. Offit, MD Division of Infectious Diseases Vaccine Education Center Children s Hospital of Philadelphia Perelman School of Medicine The University of Pennsylvania Topics
More informationBroadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University
Broadly protective influenza vaccines for pandemic preparedness Suresh Mittal Department of Comparative Pathobiology Purdue University Influenza A Virus Orthomyxovirus Consist of s/s (-) sense RNA 8 segments
More informationInfluenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Influenza viruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped particles, quasi-spherical or filamentous Diameter 80-120 nm Envelope is derived
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More informationChallenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats
Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. BIO 2009 Process Zone Theater Atlanta, GE May 20, 2009
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More information7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?
What is a correlate of protection? Immunological Assessment of Influenza Vaccines and Correlates of Protection Jacqueline Katz Influenza Division Centers for Disease Control and Prevention Defined immune
More informationVaccine Technology II June 1-6, 2008 (Albufeira, Algarve, Portugal) FluBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine.
Vaccine Technology II June 1-6, 2008 (Albufeira, Algarve, Portugal) FluBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine Manon Cox June 2, 2008 A Vaccine Company for the 21st Century Making
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationNew Vaccines Against Influenza Virus
Georgia State University ScholarWorks @ Georgia State University Biology Faculty Publications Department of Biology 2014 New Vaccines Against Influenza Virus Young-Tae Lee Georgia State University Ki-Hye
More informationAssessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationDevelopment of live attenuated pediatric RSV vaccines
Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV
More informationVirus-like particles as universal influenza vaccines
Virus-like particles as universal influenza vaccines Sang-Moo Kang, Georgia State University Min-Chul Kim, Emory University Richard W Compans, Emory University Journal Title: Expert Review of Vaccines
More informationImproving Influenza vaccines: Looking ahead
Improving Influenza vaccines: Looking ahead Gerd Sutter gerd.sutter@lmu.de ESWI Flu Summit - Brussels 30.09.2015 First 20th century pandemic - The Spanish Flu Courtesy: A. Garcia-Sastre Influenza A/CDC/1918
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationViral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More informationMedicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationInfluenza vaccines. Cheryl Cohen
Influenza vaccines Cheryl Cohen cherylc@nicd.ac.za Overview Burden of influenza and risk groups Clinical presentation, diagnosis and treatment Influenza the virus Currently available influenza vaccines
More information100 years of Influenza Pandemic and the prospects for new influenza vaccines
100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London
More informationResearch: Sanofi Pasteur, Medimrnune (AstraZeneca), Pfizer, Diassess, Novavax, Merck, GSK, Regeneron, Janssen, Novartis
Joseph Domachowske MD, FAAP Professor of Pediatrics Professor of Microbiology and Immunology SUNY Upstate Medical University Syracuse, NY Consultant: Sanofi Pasteur, Medimmune Research: Sanofi Pasteur,
More informationStrategies for control of influenza by targeting broadly conserved viral features
Strategies for control of influenza by targeting broadly conserved viral features Forum on Microbial Threats Institute of Medicine June 16, 2004 Suzanne Epstein, Ph.D. Laboratory of Immunology and Developmental
More informationRequirements for quality control and registration of influenza vaccines developed using novel biotechnological approaches
WHO Integrated Meeting on development and clinical trials of Influenza vaccines Hongkong, January 2013 www.pei.de Requirements for quality control and registration of influenza vaccines developed using
More informationFoot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
More informationRalf Wagner Paul-Ehrlich-Institut
www.pei.de Other Assays for the Detection of Neuraminidase (NA)-Specific Antibodies Ralf Wagner Paul-Ehrlich-Institut Overview to presented assays Assay principle based on: Chemical substrates: Protein
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationThe Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines
The Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines Kathleen Neuzil, MD, MPH Director, Center for Vaccine Development University of Maryland School of Medicine September
More information7/14/2014 VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD)
7/14/214 VACCINATION & ENHANCED DISEASE VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD) HANA GOLDING & SURENDER KHURANA DIVISION OF VIRAL
More informationVIRUSES. Biology Applications Control. David R. Harper. Garland Science Taylor & Francis Group NEW YORK AND LONDON
VIRUSES Biology Applications Control David R. Harper GS Garland Science Taylor & Francis Group NEW YORK AND LONDON vii Chapter 1 Virus Structure and 2.2 VIRUS MORPHOLOGY 26 Infection 1 2.3 VIRAL CLASSIFICATION
More informationInnate Immunity & Inflammation
Innate Immunity & Inflammation The innate immune system is an evolutionally conserved mechanism that provides an early and effective response against invading microbial pathogens. It relies on a limited
More informationImpact of influenza vaccination on influenza antibody response and unplanned hospital admissions
Impact of influenza vaccination on influenza antibody response and unplanned hospital admissions among community-dwelling Chinese elderly in Hong Kong A randomised controlled trial Dr. L. W. Chu Consultant,
More informationRespiratory Viruses. Respiratory Syncytial Virus
Adam Ratner, MD Respiratory Viruses Respiratory viruses are among the most common causes of disease throughout life. Often mild and self-limited, they are still associated with tremendous economic and
More informationSynthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)
Synthetic Genomics and Its Application to Viral Infectious Diseases Timothy Stockwell (JCVI) David Wentworth (JCVI) Outline Using informatics to predict drift (strain selection) Synthetic Genomics: Preparedness
More informationRevision of the RVF chapter in the OIE Terrestrial Manuel D.Goovaerts, IFAH. Mombasa, November 14 th 2012
Revision of the RVF chapter in the OIE Terrestrial Manuel D.Goovaerts, IFAH Mombasa, November 14 th 2012 Meeting of OIE ad hoc group on RVF Paris meeting October 9-11 th Chapter 2.1.14 of the Manual on
More informationCristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
More informationEMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More informationDevelopment of a Novel Recombinant Influenza Vaccine in Insect Cells
Development of a Novel Recombinant Influenza Vaccine in Insect Cells Clifton McPherson New Cells for New Vaccines II September 18, 2007 cmcpherson@proteinsciences.com New Cell for New Vaccines II Topics:
More informationVACCINE ENGINEERING Dr.T.V.Rao MD
VACCINE ENGINEERING Dr.T.V.Rao MD DR.T.V.RAO MD 1 HISTORICAL PICTURE OF VACCINATION DR.T.V.RAO MD 2 WHAT IS A VACCINE A vaccine is any preparation intended to produce immunity to a disease by stimulating
More informationC E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock
C E E Z A D Center of Excellence for Emerging and Zoonotic Animal Diseases A Department of Homeland Security Center of Excellence Rational Development of Influenza Vaccines: NDV-based influenza vaccines
More informationChallenges and Solutions for the Next Generation of Vaccines: Jonathan Liu Luis Maranga Sachin Mani Richard Schwartz
Challenges and Solutions for the Next Generation of Vaccines: Development of fcell llculture-based dlive Attenuated t Influenza Vaccine VACCINE TECHNOLOGY II June 1, 2008 Albufeira (near Faro), Algarve,
More informationCorrelates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer
Correlates of Protection for Flu vaccines and Assays Overview by Simona Piccirella, PhD Chief Executive Officer Company Overview: VisMederi is an Italian private small enterprise established in 2009 and
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationInfluenza Vaccines: Giving the Right Dose at the Right Time. Agenda
Influenza Vaccines: Giving the Right Dose at the Right Time Wednesday, December 9, 2015 12:00 PM ET Agenda Agenda Welcome and Introduction William Schaffner, MD, NFID Medical Director Influenza Vaccines:
More informationHuman metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653)
Human metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653) Conference Call February 12, 2019 Flu H10N8 H7N9 Prophylactic vaccines RSV VZV CMV hmpv+piv3 Chikungunya VLP Zika VLP Cancer
More informationImmunization Update Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist
Immunization Update 2018 Dennis D. Stanley, BPharm Publix Pharmacy Vaccine and Travel Health Specialist Disclosures Merck speakers bureau Vaxserve speakers bureau Mrs. Jones shows up for her second ShingRix
More informationThe DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses
JOURNAL OF VIROLOGY, Dec. 2011, p. 12825 12829 Vol. 85, No. 23 0022-538X/11/$12.00 doi:10.1128/jvi.05930-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The DBA.2 Mouse Is Susceptible
More informationhttp://nmhm.washingtondc.museum/collections/archives/agalleries/1918flu/ncp1603.jpg 1 https://assets-production-webvanta-com.s3-us-west- 2 2.amazonaws.com/000000/47/62/original/images/img_109_influenza/Spanish_flu_death_chart.jpg
More informationOverview: Chapter 19 Viruses: A Borrowed Life
Overview: Chapter 19 Viruses: A Borrowed Life Viruses called bacteriophages can infect and set in motion a genetic takeover of bacteria, such as Escherichia coli Viruses lead a kind of borrowed life between
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationInfluenza Vaccination by Classical Intradermal (ID) Route, Influenza Vaccination by Classical Intradermal (ID) Route,
Influenza Vaccination by Classical Intradermal (ID) Route, 1937-2007 Meeting on Fondation Mérieux, Les Pensières, Veyrier-du-Lac (Annecy), France 7-9 April 2008 Bruce G. Weniger, MD, MPH Vaccine Technology
More informationExpedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines
Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Preamble On 11 June 2009, WHO declared an influenza pandemic caused by influenza A (H1N1) 2009 virus 1. On 13 July 2009, WHO
More informationA Rationally Designed Form of The TLR5 Agonist, Flagellin, Supports Superior Immunogenicity of Influenza B Globular Head Vaccines
A Rationally Desined Form of The TLR5 Aonist, Flaellin, Supports Superior Immunoenicity of Influenza B Globular Head Vaccines Lanzhou Son VaxInnate Corporation September 26, 2014 VaxInnateInfluenza Vaccine
More informationBIO CEO & Investor Conference February 2006
BIO CEO & Investor Conference February 2006 Safe Harbor Statements made in this press release that state Novavax's or its management's intentions, hopes, beliefs, expectations, or predictions are forward-looking
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ehrlich HJ, Müller M, Oh HML, et al. A clinical trial of a
More informationNew prospects for vaccination: from polio to dengue and flu
New prospects for vaccination: from polio to dengue and flu From ancient Chinese variolation to Jenner and cowpox Paul Young Australian Infectious Diseases Research Centre School of Chemistry and Molecular
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInfluenza: Seasonal, Avian, and Otherwise
Influenza: Seasonal, Avian, and Otherwise Lisa Winston, MD University of California, San Francisco San Francisco General Hospital Influenza biology Antiviral medications Seasonal influenza Vaccination
More informationHuman Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١
Human Influenza Dr. Sina Soleimani Human Viral Vaccine Quality Control 89/2/29 November 2, 2011 HVVQC ١ Presentation outline 1. Introduction 2. Virology 3. Classification 4. Hosts 5. Antigenic Specifications
More informationHAI and NAI as Correlates of Protection After Influenza Vaccination
HAI and NAI as Correlates of Protection After Influenza Vaccination Arnold S. Monto Thomas Francis Jr. Professor University of Michigan School of Public Health Ann Arbor, Michigan Having Correlates is
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationBARDA INFLUENZA PROGRAM OVERVIEW
BARDA INFLUENZA PROGRAM OVERVIEW Drs. Armen Donabedian and Michael Wathen Vaccines and Therapeutics Resilient People. Healthy Communities. A Nation Prepared. 0 BARDA Overview 1 Perpetual challenge of responding
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationInfluenza Vaccine Innovation
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Influenza Vaccine Innovation New Vaccines Approved and on the Way Rick A. Bright, Ph.D.
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationTechnical and Regulatory Considerations in Rapid Scale-Up of Vaccine Manufacturing Processes
Technical and Regulatory Considerations in Rapid Scale-Up of Vaccine Manufacturing Processes Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. Vaccine Scale up and Manufacturing Conference
More informationThe challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute
The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200
More information